Alzheimer’s disease, treatment

Greig NH, Utsuki T, Yu QS, A new therapeutic target in Alzheimer s disease treatment, attention to butyrylcholinesterase, Curr Med Res Opin 17 159—165, 2001. [Pg.420]

Nonannulated aminopyrans 22 and tetrahydrochromenes 104 were used in the synthesis of heteroanalogs 294 and 295 of tacrine 302, a cholinesterase inhibitor applied in Alzheimer s disease treatment (01BML727, 02BML2077, 04BMC2199, 05BMC1167, 06BMC8176). [Pg.243]

Zamar AC, Wise ME, Watson JP. New drug treatment for Alzheimer s disease. Treatment with metrifonate warrants multicentre trials. BMJ 1998 317(7163) 946. [Pg.637]

The rationale and design of the first multicenter study of (-)-deprenyl in the treatment of Alzheimer s disease using novel clinical outcomes was published by Sano et al. in 1996 and the results of this study were published 1 year later (Sano et al. 1997). The primary outcome involved the time that elapses until the occurrence of any of the following death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia. There were significant delays in the time taken for such primary outcomes to occur in patients treated with (-)-deprenyl. The authors concluded that in patients with moderately severe impairment from Alzheimer s disease, treatment with (-)-deprenyl slows the progression of the disease. [Pg.93]

Weinreb O, Amit T, Bar-Am O, Youdim MB (2012) Ladostigil A novel multimodal neu-roprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer s disease treatment. Curr Drug Targets 13 483-494... [Pg.527]

Spilovska K, Korabecny J, Krai J, Horova A, Musilek K, Soukup O et al (2013) 7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer s disease treatment-synthesis, biological evaluation and molecular modeling studies. Molecules 18 2397-2418... [Pg.528]

Wang J, Ferruzzi MG, Ho L, Blount J, Janie EM, Gong B et al (2012) Brain-targeted pro-anthocyanidin metabolites for Alzheimer s disease treatment. J Neurosci 32 5144-5150... [Pg.531]

Byeon SR, Kim LTV, Jeon M, Ahn YG, Kim MS, Kong JY et al (2013) Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer s disease treatment. Bioorg Med Chem Lett 23 3467-3469... [Pg.537]

Heo JH, Hyon-Lee LKM (2013) The possible role of antioxidant vitamin C in Alzheimer s disease treatment and prevention. Am J Alzheimers Dis Other Demen 28 120-125... [Pg.542]

Raskind MA, Barnes RE Alzheimer s disease Treatment of noncog-nitive behavioral abnormalities. In Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology The Fifth Generation of Progress. New York, Lippincott Williams Wilkins, 2002 1253-1265. [Pg.1172]

Alzheimer s disease treatment of Aminoglycoside antibiotics Analgesics narcotics Analgesics non-narcotic agents Androgenic steroids Anesthetics inhalation... [Pg.807]

Tomita T (2009) Alzheimer s disease treatment by inhibition/modulation of the gamma-secretase activity. Rinsho Shinkeigaku 49 845-847... [Pg.380]

Musial A, Bajda M, Malawska B (2007) Recent developments in cholinesterases inhibitors for Alzheimer s disease treatment. Curr Med Chem 14 2654—2679... [Pg.1359]

Geng, J., Li, M., Wu, L., Chen, C., and Qu, X. (2012) Mesoporous silica nanoparticle-based H2O2 responsive controlled-release system used for Alzheimer s disease treatment Adv. Healthcare Mater., 1 (3), 332-336. [Pg.1340]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...